INDIA – Abbott has rolled out the FreeStyle LibreLink app designed specifically for Indian users of the FreeStyle Libre glucose monitoring system.

“At Abbott, we are committed to ensuring our FreeStyle Libre technology not only simplifies the daily routines for people living with diabetes but also empowers them to manage their diabetes more effectively,” Kalyan Sattaru, General Manager of Abbott’s Diabetes Care Business in South Asia, said in a statement.

According to the Company’s press statement, the FreeStyle LibreLink app is compatible with both iPhone and Android smartphones.

The FreeStyle LibreLink app provides users the convenience of checking their readings on their mobile phones without the need for finger pricking.

With the release of this new app, Abbott intends to not only offer real-time glucose data but also ensure users can easily share information with healthcare providers.

People living with diabetes experience significant burden as they face a multitude of tasks to effectively manage their diabetes. FreeStyle LibreLink app seamlessly integrates with FreeStyle Libre sensor,” highlighted Kalyan Sattaru.

The mobile app is designed to be engaging, interactive, and effective, leveraging the latest technology, including near-field communication (NFC) technology.

Using NFC technology, the FreeStyle LibreLink app transfers glucose data from the sensor to the mobile device to allow users to track and share blood sugar results.

Smartphone users can track their eight-hour glucose history and real-time patterns for better management of diet, insulin use, medication, and exercise—all without requiring a separate reader for glucose monitoring.

In a related news story, Abbott recently launched its new vascular imaging platform powered by Ultreon 1.0 Software in India.

The intra-vascular imaging software combines optical coherence tomography (OCT) with the power of artificial intelligence (AI) providing physicians a comprehensive view of blood flow and blockages within coronary arteries.

The innovative imaging software can automatically differentiate between a calcified and non-calcified blockage, detect the severity of calcium-based blockages and measure vessel diameter.

In addition, it helps physicians guide precise stent deployment, ensuring optimal stent expansion and apposition with instantaneous display of results to enhance precision during coronary stenting procedures.

Consequently, the launch of the FreeStyle LibreLink mobile app marks a significant milestone in Abbott’s quest for excellence in diabetes care.

Its long-awaited launch signifies a move towards healthcare that is not only more accessible but also more personalised, convenient, and empowering.

Commenting on this news, Dr. Manoj Chawla, Senior Diabetologist said: “The ability to automatically receive glucose information on a real-time basis can facilitate easier diabetes management for people with diabetes and their caregivers. New diabetes technology will pave the way for precise and informed decision-making.”

In an unprecedented news story, Abbott is set to cease sales of its Similac Probiotic Tri-Blend product used for hospitalised preterm infants after the U.S. Food and Drug Administration issued a warning letter.